Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, nationwide pet pharmacy PetMed Express (NASDAQ:PETS) has earned a respected four-star ranking.

With that in mind, let's take a closer look at PetMed's business, and see what CAPS investors are saying about the stock right now.

PetMed facts 

Headquarters (founded)

Pompano Beach, Fla. (1996)

Market Cap

$359.37 million


Internet retail

TTM Revenue

$211.76 million


CEO Menderes Akdag (since 2001)
CFO Bruce Rosenbloom (since 2001)

Return on Capital (average, last three years)



MWI Veterinary Supply (NASDAQ:MWIV)
Nyer Medical

CAPS members bullish on PETS also bullish on

Johnson & Johnson (NYSE:JNJ)
General Electric (NYSE:GE)

CAPS members bearish on PETS also bearish on

General Motors (NYSE:GM)
Ford Motor (NYSE:F)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, fully 609 of the 627 members who have rated PetMed -- some 97% -- believe the stock will outperform the S&P 500 going forward. These bulls include mespanol and elmosworld.

Late last month, mespanol recommended PetMed for any portfolio illness: "small cap, good management, positive cash flow, no debt, the leader in the online pet prescription niche. Conclusion: strong buy."

In a pitch from January, elmosworld helps support that sentiment with an anecdotal example:

I like the franchise Petmed Express has built over the years. Despite the challenging industry dynamic that veterinarians present, I still think that the cost efficiencies that [PetMed] passes to customers will continue to gain traction thereby garnering greater market share over time. For example, my lab has had severe skin allergies in the past. After numerous appointments and trial and error with various medications, we found one that seemed to work well, but was very costly -- to the tune of $300 per month. I found the same brand name med on [PetMed] website for half the price.

What do you think about PetMed, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick, and Apple is a selection of Stock Advisor. The Fool's disclosure policy always gets a perfect score.